secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIO-TECHNE Corp (TECH)
CIK:        0000842023
Form:       8-K
Filed at:   2026-02-04T23:59:59+00:00
Accession:  0001104659-26-009994
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bio-Techne Q2 revenue flat at $295.9M; adjusted EPS rises to $0.46 from $0.42
-----------------------------------------------------------------------------

- GAAP EPS of $0.24 vs $0.22; adjusted EPS of $0.46 vs $0.42, both year-over-year increases.
- Protein Sciences segment revenue +2% to $215.1M; operating margin fell to 39.3% from 41.2%.
- Diagnostics & Spatial Biology segment revenue -4% to $81.2M; organic growth +3% with margin up to 10.4%.
- Board declares $0.08/share quarterly dividend, payable Feb 27, 2026 to holders of record Feb 16, 2026.
- China/APAC region drove growth for third consecutive quarter; large pharma end-market grew double digits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/0001104659-26-009994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/842023/000110465926009994/tech-20260204x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-009994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer